Phospshoinositide 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Dual Inhibitors: Discovery and Structure–Activity Relationships of a Series of Quinoline and Quinoxaline DerivativesNobuko Nishimura, Mark H. Norman, Hongyu Liao et al.|Journal of Medicinal Chemistry|2011Cited by 60
Structure-Based Design of a Novel Series of Potent, Selective Inhibitors of the Class I Phosphatidylinositol 3-KinasesAdrian L. Smith, Mark H. Norman, Noel D. D’Angelo et al.|Journal of Medicinal Chemistry|2012Cited by 50
Selective Class I Phosphoinositide 3-Kinase Inhibitors: Optimization of a Series of Pyridyltriazines Leading to the Identification of a Clinical Candidate, AMG 511Mark H. Norman, Paul E. Hughes, Kristin L. Andrews et al.|Journal of Medicinal Chemistry|2012Cited by 50
Structure–Activity Relationships of Phosphoinositide 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Dual Inhibitors: Investigations of Various 6,5-Heterocycles to Improve Metabolic StabilityMarkian M. Stec, Mark H. Norman, Kristin L. Andrews et al.|Journal of Medicinal Chemistry|2011Cited by 44
Synthesis and structure–activity relationships of dual PI3K/mTOR inhibitors based on a 4-amino-6-methyl-1,3,5-triazine sulfonamide scaffoldRyan P. Wurz, Mark H. Norman, Longbin Liu et al.|Bioorganic & Medicinal Chemistry Letters|2012Cited by 30